ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Update on Priority Review by CDE: Acceptance of First CAR-T Therapy Clinical Application
February 02, 2018On December 11, 2017, the first CAR-T project clinical application in China (CXSL1700201) filed by Nanjing Legend Biotechnology Co., Ltd. (hereinafter referred to as Nanjing Legend) was formally undertaken and accepted by the CDE -
Update on Priority Review by CDE: Biggest Bright Spot Being the Inclusion of Novartis’ LCZ696
January 31, 2018CDE publicized on December 2 the twelfth batch of registration applications of pharmaceutical products to be included in the priority review procedure, with 32 acceptance numbers in total included in the list. -
“BioTaiwan, China's growth is a reflection of the success of Taiwan, China biotech as a whole in recent years.”
August 10, 2017BioSpectrum Asia recently spoke to Dr Apo Huang, Secretary General, BioTaiwan, China on the current growth in the Taiwan, Chinaese biotech sector. -
Analysis of the Policy Signals in the 2016 Drug Review Annual Report of CDE
March 31, 2017CDE (Center for Drug Evaluation, CFDA) issued 2016 Drug Review Annual Report on March 17, 2017.
Pharma Sources Insight January 2025
